HOOKIPA Pharma Inc
HOOK0.840USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
10.14MMarket Cap
LossP/E TTM
More Details of HOOKIPA Pharma Inc Company
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
HOOKIPA Pharma Inc Info
Ticker SymbolHOOK
Company nameHOOKIPA Pharma Inc
IPO dateApr 18, 2019
CEODr. Malte Peters, M.D.
Number of employees82
Security typeOrdinary Share
Fiscal year-endApr 18
Address350 Fifth Avenue, 72Nd Floor, Suite 7240
CityNEW YORK
Stock exchangeUS 'Other OTC' and Grey Market
CountryUnited States of America
Postal code10118
Phone114318906360
Websitehttps://www.hookipapharma.com/
Ticker SymbolHOOK
IPO dateApr 18, 2019
CEODr. Malte Peters, M.D.
Company Executives of HOOKIPA Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
496.00
-0.20%
Mr. Sean A. Cassidy
Mr. Sean A. Cassidy
Independent Director
Independent Director
--
--
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Dr. David R. Kaufman, M.D., Ph.D.
Dr. David R. Kaufman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Terry Coelho
Ms. Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Chief Financial Officer, Executive Vice President, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
496.00
-0.20%
Mr. Sean A. Cassidy
Mr. Sean A. Cassidy
Independent Director
Independent Director
--
--
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Dr. David R. Kaufman, M.D., Ph.D.
Dr. David R. Kaufman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Terry Coelho
Ms. Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Chief Financial Officer, Executive Vice President, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
5.02%
JBF Capital, Inc.
3.49%
Sofinnova Partners
3.16%
Acadian Asset Management LLC
0.28%
XTX Markets LLC
0.18%
Other
87.86%
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
5.02%
JBF Capital, Inc.
3.49%
Sofinnova Partners
3.16%
Acadian Asset Management LLC
0.28%
XTX Markets LLC
0.18%
Other
87.86%
Shareholder Types
Shareholders
Proportion
Hedge Fund
5.02%
Investment Advisor
3.51%
Venture Capital
3.35%
Investment Advisor/Hedge Fund
0.28%
Individual Investor
0.13%
Other
87.71%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
82
2.93M
29.47%
-1.44M
2025Q2
100
5.23M
53.41%
-1.43M
2025Q1
107
5.24M
53.53%
-1.53M
2024Q4
113
5.54M
57.39%
-1.29M
2024Q3
117
5.65M
62.13%
+370.86K
2024Q2
126
5.73M
65.67%
+16.62K
2024Q1
159
5.79M
66.36%
+211.50K
2023Q4
171
5.72M
72.26%
+846.00
2023Q3
186
4.97M
68.46%
-1.10M
2023Q2
191
5.35M
75.93%
+1.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Knoll Capital Management, LLC
498.63K
5.02%
--
--
Jun 30, 2025
Sofinnova Partners
314.26K
3.16%
+314.26K
--
Feb 14, 2025
Acadian Asset Management LLC
55.73K
0.56%
--
--
Jun 30, 2025
Aldag (Jorn)
7.20K
0.07%
--
--
Jun 04, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
Date
Type
Ratio
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
Jul 08, 2024
Merger
10→1
FAQs
Who are the top five shareholders of HOOKIPA Pharma Inc?
The top five shareholders of HOOKIPA Pharma Inc are:
Knoll Capital Management, LLC holds 498.63K shares, accounting for 5.02% of the total shares.
Sofinnova Partners holds 314.26K shares, accounting for 3.16% of the total shares.
Acadian Asset Management LLC holds 55.73K shares, accounting for 0.56% of the total shares.
Aldag (Jorn) holds 7.20K shares, accounting for 0.07% of the total shares.
Knoll Capital Management, LLC holds 498.63K shares, accounting for 5.02% of the total shares.
Sofinnova Partners holds 314.26K shares, accounting for 3.16% of the total shares.
Acadian Asset Management LLC holds 55.73K shares, accounting for 0.56% of the total shares.
Aldag (Jorn) holds 7.20K shares, accounting for 0.07% of the total shares.
What are the top three shareholder types of HOOKIPA Pharma Inc?
The top three shareholder types of HOOKIPA Pharma Inc are:
Knoll Capital Management, LLC
JBF Capital, Inc.
Sofinnova Partners
Knoll Capital Management, LLC
JBF Capital, Inc.
Sofinnova Partners
How many institutions hold shares of HOOKIPA Pharma Inc (HOOK)?
As of 2025Q3, 82 institutions hold shares of HOOKIPA Pharma Inc, with a combined market value of approximately 2.93M, accounting for 29.47% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -23.94%.
What is the biggest source of revenue for HOOKIPA Pharma Inc?
In --, the -- business generated the highest revenue for HOOKIPA Pharma Inc, amounting to -- and accounting for --% of total revenue.
